Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%
HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

At a Glance

Live Snapshot
Market Cap$70.67M
EPS-0.2500
P/E Ratio-5.74
Earnings Date02/12/2026

aneb

Total Stockholders' Equity

Last Annual Value

11.66M

3-Year CAGR

-8%

5-Year CAGR

134%

10-Year CAGR

53%

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Competitors Analysis of Total Stockholders' Equity

ANEB · NASDAQ
CompanyTotal Stockholders' Equity
CAGR 3Y
CAGR 5Y
CAGR 10Y
11.66M
3.2%-11.4%N/A 
CLNN logo
Clene Inc.
NASDAQ:CLNN
-17.59M
N/AN/AN/A
93.80M
78.8%39.1%N/A
216.20M
-20.9%-9.9%N/A
67.48M
-9.4%-9.2%0.7%
29.55M
-44.1%-30.2%N/A
EXOZ logo
eXoZymes, Inc.
NASDAQ:EXOZ
3.40M
N/A23.2%N/A
9.46M
N/AN/AN/A
199.74M
6.8%11.5%22.5%
30.15M
-29.2%-24.0%N/A
42.52M
-17.8%-17.5%N/A
Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Fair Value Envelope

ANEB · NASDAQ

Our analysis suggests that ANEB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.72, this represents a potential HIDDEN relative to our calculated worth for Anebulo Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $1.72